Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 408047, 7 pages
http://dx.doi.org/10.1155/2014/408047
Review Article

Levels of Soluble E-Cadherin in Breast, Gastric, and Colorectal Cancers

1Facility of Bio-Proteomics, Centro di Riferimento Oncologico (CRO), Aviano National Cancer Institute, Via F. Gallini 2, 33081 Aviano, Italy
2Centro di Riferimento Oncologico (CRO), Aviano National Cancer Institute, Via F. Gallini 2, 33081 Aviano, Italy
3Pathology Unit, Centro di Riferimento Oncologico (CRO), Aviano National Cancer Institute, Via F. Gallini 2, 33081 Aviano, Italy
4Gastroenterology Unit, Centro di Riferimento Oncologico (CRO), Aviano National Cancer Institute, Via F. Gallini 2, 33081 Aviano, Italy

Received 3 February 2014; Accepted 18 August 2014; Published 16 September 2014

Academic Editor: Alessandro Luciani

Copyright © 2014 Ombretta Repetto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. J. Nelson, D. J. Dickinson, and W. I. Weis, “Roles of cadherins and catenins in cell-cell adhesion and epithelial cell polarity,” Progress in Molecular Biology and Translational Science, vol. 116, pp. 3–23, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Twiss and J. De Rooij, “Cadherin mechanotransduction in tissue remodeling,” Cellular and Molecular Life Sciences, vol. 70, no. 21, pp. 4101–4116, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Tsanou, D. Peschos, A. Batistatou, A. Charalabopoulos, and K. Charalabopoulos, “The E-cadherin adhesion molecule and colorectal cancer. A global literature approach,” Anticancer Research, vol. 28, no. 6, pp. 3815–3826, 2008. View at Google Scholar · View at Scopus
  4. F. van Roy and G. Berx, “The cell-cell adhesion molecule E-cadherin,” Cellular and Molecular Life Sciences, vol. 65, no. 23, pp. 3756–3788, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Halbleib and W. J. Nelson, “Cadherins in development: cell adhesion, sorting, and tissue morphogenesis,” Genes and Development, vol. 20, no. 23, pp. 3199–3214, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. W.-H. Lien, O. Klezovitch, and V. Vasioukhin, “Cadherin-catenin proteins in vertebrate development,” Current Opinion in Cell Biology, vol. 18, no. 5, pp. 499–506, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. B. M. Gumbiner, “Regulation of cadherin-mediated adhesion in morphogenesis,” Nature Reviews Molecular Cell Biology, vol. 6, no. 8, pp. 622–634, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Gheldof and G. Berx, “Cadherins and epithelial-to-mesenchymal transition,” Progress in Molecular Biology and Translational Science, vol. 116, pp. 317–336, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Canel, A. Serrels, M. C. Frame, and V. G. Brunton, “E-cadherin-integrin crosstalk in cancer invasion and metastasis,” Journal of Cell Science, vol. 126, no. 2, pp. 393–401, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. F. J. Rodriguez, L. J. Lewis-Tuffin, and P. Z. Anastasiadis, “E-cadherin's dark side: possible role in tumor progression,” Biochimica et Biophysica Acta: Reviews on Cancer, vol. 1826, no. 1, pp. 23–31, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Jeanes, C. J. Gottardi, and A. S. Yap, “Cadherins and cancer: how does cadherin dysfunction promote tumor progression?” Oncogene, vol. 27, no. 55, pp. 6920–6929, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. R. B. Hazan, R. Qiao, R. Keren, I. Badano, and K. Suyama, “Cadherin switch in tumor progression,” Annals of the New York Academy of Sciences, vol. 1014, pp. 155–163, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. A. M. Todosi, M. M. Gavrilescu, G. M. Anitei, B. Filip, and V. Scripcariu, “Colon cancer at the molecular level—usefulness of epithelial-mesenchymal transition analysis,” Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi's, vol. 116, pp. 1106–1111, 2012. View at Google Scholar
  14. J. Figueiredo, O. Söderberg, J. Simões-Correia, K. Grannas, G. Suriano, and R. Seruca, “The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC,” European Journal of Human Genetics, vol. 21, no. 3, pp. 301–309, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Simões-Correia, J. Figueiredo, R. Lopes et al., “E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer,” PLoS ONE, vol. 7, no. 3, Article ID e33783, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. K.-F. Becker, M. J. Atkinson, U. Reich et al., “E-cadherin gene mutations provide clues to diffuse type gastric carcinomas,” Cancer Research, vol. 54, no. 14, pp. 3845–3852, 1994. View at Google Scholar · View at Scopus
  17. K. Chu, K. M. Boley, R. Moraes, S. H. Barsky, and F. M. Robertson, “The paradox of E-cadherin: role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism,” Oncotarget, vol. 4, no. 3, pp. 446–462, 2013. View at Google Scholar · View at Scopus
  18. S. Baranwal and S. K. Alahari, “Molecular mechanisms controlling E-cadherin expression in breast cancer,” Biochemical and Biophysical Research Communications, vol. 384, no. 1, pp. 6–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. T. L. Mastracci, S. Tjan, A. L. Bane, F. P. O'Malley, and I. L. Andrulis, “E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast,” Modern Pathology, vol. 18, no. 6, pp. 741–751, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Berx, A.-M. Cleton-Jansen, K. Strumane et al., “E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain,” Oncogene, vol. 3, no. 9, pp. 1919–1925, 1996. View at Google Scholar · View at Scopus
  21. Y.-E. Joo, J.-S. Rew, S.-K. Choi, H.-S. Bom, C.-S. Park, and S.-J. Kim, “Expression of E-cadherin and catenins in early gastric cancer,” Journal of Clinical Gastroenterology, vol. 35, no. 1, pp. 35–42, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Berx, A.-M. Cleton-Jansen, F. Nollet et al., “E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers,” EMBO Journal, vol. 14, no. 24, pp. 6107–6115, 1995. View at Google Scholar · View at Scopus
  23. G. Berx, K. F. Becker, H. Höfler, and F. van Roy, “Mutations of the human E-cadherin (CDH1) gene,” Human Mutation, vol. 12, pp. 226–237, 1998. View at Google Scholar
  24. A. Hollestelle, J. K. Peeters, M. Smid et al., “Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer,” Breast Cancer Research and Treatment, vol. 138, no. 1, pp. 47–57, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. M. Grabowska and M. L. Day, “Soluble E-cadherin: more than a symptom of disease,” Frontiers in Bioscience, vol. 17, no. 5, pp. 1948–1964, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. O. de Wever, L. Derycke, A. Hendrix et al., “Soluble cadherins as cancer biomarkers,” Clinical and Experimental Metastasis, vol. 24, no. 8, pp. 685–697, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Katayama, S. Hirai, K. Kamihagi, K. Nakagawa, M. Yasumoto, and I. Kato, “Soluble E-cadherin fragments increased in circulation of cancer patients,” British Journal of Cancer, vol. 69, no. 3, pp. 580–585, 1994. View at Publisher · View at Google Scholar · View at Scopus
  28. A. R. Parrish, J. M. Catania, J. Orozco, and A. J. Gandolfi, “Chemically induced oxidative stress disrupts the E-cadherin/catenin cell adhesion complex,” Toxicological Sciences, vol. 51, no. 1, pp. 80–86, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. A. J. Karayiannakis, K. N. Syrigos, A. Savva, A. Polychronidis, G. Karatzas, and C. Simopoulos, “Serum E-cadherin concentrations and their response during laparoscopic and open cholecystectomy,” Surgical Endoscopy and Other Interventional Techniques, vol. 16, no. 11, pp. 1551–1554, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Katayama, K. Kamihagi, S. Hirai et al., “Urinary laminin fragments as a tumour marker potentially reflecting basement membrane destruction,” British Journal of Cancer, vol. 65, no. 4, pp. 509–514, 1992. View at Publisher · View at Google Scholar · View at Scopus
  31. L. G. Perez-Rivas, J. M. Jerez, C. E. Fernandez-De Sousa et al., “Serum protein levels following surgery in breast cancer patients: a protein microarray approach,” International Journal of Oncology, vol. 41, no. 6, pp. 2200–2206, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Mueller, L. A. Liotta, and V. Espina, “Reverse phase protein microarrays advance to use in clinical trials,” Molecular Oncology, vol. 4, no. 6, pp. 461–481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Hofmann, N. Dandachi, M. Balic et al., “Quantitative measurement of soluble E-cadherin in sera of breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy and its predictive and prognostic value,” Journal of Clinical Oncology, vol. 23, supplement 768, Meeting abstracts, no. 16, 2005. View at Google Scholar
  34. L. Dollé, M.-J. Oliveira, E. Bruyneel, H. Hondermarck, and M. Bracke, “Nerve Growth Factor mediates its pro-invasive effect in parallel with the release of a soluble E-cadherin fragment from breast cancer MCF-7/AZ cells,” Journal of Dairy Research, vol. 72, pp. 20–26, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Hofmann, M. Balic, N. Dandachi et al., “The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy,” Clinical Biochemistry, vol. 46, no. 15, pp. 1585–1589, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. S. M. Brouxhon, S. Kyrkanides, X. Teng et al., “Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers,” Molecular Carcinogenesis, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. S. M. Brouxhon, S. Kyrkanides, X. Teng et al., “Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling,” Oncogene, vol. 33, no. 2, pp. 225–235, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. A. O. O. Chan, K.-M. Chu, S. K. Lam et al., “Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin,” Cancer, vol. 104, no. 4, pp. 740–746, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. A. O.-O. Chan, K.-M. Chu, S.-K. Lam et al., “Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer,” Journal of Clinical Oncology, vol. 21, no. 12, pp. 2288–2293, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Juhasz, M. P. A. Ebert, H. U. Schulz et al., “Dual role of serum soluble E-cadherin as a biological marker of metastatic development in gastric cancer,” Scandinavian Journal of Gastroenterology, vol. 38, no. 8, pp. 850–855, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. A. O. O. Chan, S. K. Lam, K. M. Chu et al., “Soluble E-cadherin is a valid prognostic marker in gastric carcinoma,” Gut, vol. 48, no. 6, pp. 808–811, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Gofuku, H. Shiozaki, Y. Doki et al., “Characterization of soluble E-cadherin as a disease marker in gastric cancer patients,” British Journal of Cancer, vol. 78, no. 8, pp. 1095–1101, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Imperlini, I. Colavita, M. Caterino et al., “The secretome signature of colon cancer cell lines,” Journal of Cellular Biochemistry, vol. 114, no. 11, pp. 2577–2587, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Okugawa, Y. Toiyama, Y. Inoue et al., “Clinical significance of serum soluble E-cadherin in colorectal carcinoma,” Journal of Surgical Research, vol. 175, no. 2, pp. e67–e73, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. J. V. Weiß, S. Klein-Scory, S. Kübler et al., “Soluble E-cadherin as a serum biomarker candidate: elevated levels in patients with late-stage colorectal carcinoma and FAP,” International Journal of Cancer, vol. 128, no. 6, pp. 1384–1392, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Wilmanns, J. Grossmann, S. Steinhauer et al., “Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients,” Clinical & Experimental Metastasis, vol. 21, no. 1, pp. 75–78, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Velikova, R. E. Banks, A. Gearing et al., “Serum concentrations of soluble adhesion molecules in patients with colorectal cancer,” British Journal of Cancer, vol. 77, no. 11, pp. 1857–1863, 1998. View at Publisher · View at Google Scholar · View at Scopus
  48. A. S. Protheroe, R. E. Banks, M. Mzimba et al., “Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer,” The British Journal of Cancer, vol. 80, no. 1-2, pp. 273–278, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. T. R. L. Griffiths, I. Brotherick, R. I. Bishop et al., “Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence,” The British Journal of Cancer, vol. 74, no. 4, pp. 579–584, 1996. View at Publisher · View at Google Scholar · View at Scopus
  50. R. E. Banks, W. H. Porter, P. Whelan, P. H. Smith, and P. J. Selby, “Soluble forms of the adhesion molecule E-cadherin in urine,” Journal of Clinical Pathology, vol. 48, no. 2, pp. 179–180, 1995. View at Publisher · View at Google Scholar · View at Scopus
  51. B. Shi, V. Laudon, S. Yu, D. Dong, Y. Zhu, and Z. Xu, “E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma,” Urologia Internationalis, vol. 81, no. 3, pp. 320–324, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. S. F. Shariat, K. Matsumoto, R. Casella, W. Jian, and S. P. Lerner, “Urinary levels of soluble E-cadherin in the detection of transitional cell carcinoma of the urinary bladder,” European Urology, vol. 48, no. 1, pp. 69–76, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. G. C. Durkan, I. Brotherick, and J. K. Mellon, “The impact of transurethral resection of bladder tumour on serum levels of soluble E-cadherin,” BJU International, vol. 83, no. 4, pp. 424–428, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. K. Matsumoto, S. F. Shariat, R. Casella, T. M. Wheeler, K. M. Slawin, and S. P. Lerner, “Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy,” Journal of Urology, vol. 170, no. 6, pp. 2248–2252, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Soyama, S. Eguchi, M. Takatsuki et al., “Significance of the serum level of soluble E-cadherin in patients with HCC,” Hepato-Gastroenterology, vol. 55, no. 85, pp. 1390–1393, 2008. View at Google Scholar · View at Scopus
  56. K. N. Syrigos, E. Salgami, A. J. Karayiannakis, N. Katirtzoglou, E. Sekara, and P. Roussou, “Prognostic significance of soluble adhesion molecules in Hodgkin's disease,” Anticancer Research, vol. 24, no. 2, pp. 1243–1247, 2004. View at Google Scholar · View at Scopus
  57. K. N. Syrigos, K. J. Harrington, A. J. Karayiannakis, N. Baibas, N. Katirtzoglou, and P. Roussou, “Circulating soluble E-cadherin levels are of prognostic significance in patients with multiple myeloma,” Anticancer Research, vol. 24, no. 3, pp. 2027–2031, 2004. View at Google Scholar · View at Scopus
  58. A. Gogali, K. Charalabopoulos, I. Zampira et al., “Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers,” Chest, vol. 138, no. 5, pp. 1173–1179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Charalabopoulos, A. Gogali, Y. Dalavaga et al., “The clinical significance of soluble E-cadherin in nonsmall cell lung cancer,” Experimental Oncology, vol. 28, no. 1, pp. 83–85, 2006. View at Google Scholar · View at Scopus
  60. F. Iacopino, F. Pinto, A. Bertaccini et al., “Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy,” Oncology Reports, vol. 28, no. 1, pp. 370–374, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. R. Kuefer, M. D. Hofer, J. E. Gschwend et al., “The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer,” Clinical Cancer Research, vol. 9, no. 17, pp. 6447–6452, 2003. View at Google Scholar · View at Scopus
  62. H. C. Diehl, K. Stühler, S. Klein-Scory et al., “A catalogue of proteins released by colorectal cancer cells in vitro as an alternative source for biomarker discovery,” Proteomics: Clinical Applications, vol. 1, no. 1, pp. 47–61, 2007. View at Publisher · View at Google Scholar · View at Scopus